ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.110

-1.4%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

bobbseytwins2001

To: bobbseytwins2001 who wrote (1049)	5/29/2025 5:48:27 PM
From: Redman1234	1 Recommendation of 1229

Hedge Funds are likely basing their decision to short with the expectation of catalysts to disappoint based on past history. Manufacturing issues, RTF, and current cash burn rate. I’m still looking for UK NICE and European approval this year, but a lot rest on whether NSCLC BLA filing for AA this year or early next? NSCLC Is the money maker that proves Anktiva treats multiple cancers. With half the upper management having left or given the pink slip in FDA unfortunately there are bound to be delays which will only help Hedge Funds shorting. Taken everything into consideration I’m still buying at $3 or below with expectation of delays and news pushed back until 2026. I hope am wrong, but I am patient because I believe in Anktiva.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next